Risperdal, Gynecomastia and the Lack of Warning Labels

Risperdal drug increases a hormone called Prolactin  that is responsible for breast development in man.

Imagine, how breast growth can make our youths vulnerable to psychological trauma. To treat this condition they would have to undergo surgery, liposuction and possibly even mastectomy.

Just like any other situation where a company is trying to prove that they operated in a transparent manner, however they have yet warn anyone of the potential for gynecomastia to develop.  Simple labeling would be sufficient don’t you think?

It appears that Johnson & Johnson manufacturers targeted children and young adults, knowing that they had not obtained the necessary approvals to ensure that Risperdal drug was in fact safe to use on children. It leaves one wonderingthat  if the allegations of their negligence was driven by monetary interests? Did they fail to make the health of their consumers a priority by putting their patient’s health at risk?

Johnson & Johnson continue to stand by their claim that physicians were warned of the risks associated with the use of Risperdal drug. For more details regarding the smae, one can simply head to http://www.risperdalgynecomastialawsuitcenter.com/risperdal-male-breasts-lawsuit.asp or similar sites.

Hundreds of Riperdal gynecomastia lawsuits have been filed in U.S. courts on behalf of boys and men who allegedly experienced excessive breast growth related to use of the atypical antipsychotic medication.